Paragard Lawsuit Timeline: FDA Labeling, MDL 2974, and Bellwether Scheduling

Before the MDL: the device and its approved warnings

Paragard is a T-shaped copper intrauterine contraceptive with an FDA approval history dating to 1984. Current labeling separates several risks that are often blurred online: embedment, perforation during or after insertion, expulsion, bleeding changes, and device breakage reported after approval. These events have different mechanisms and records. A perforation at insertion is not the same event as an arm breaking during attempted removal years later.

The 2024 prescribing information says partial penetration or embedment can make removal difficult, surgical removal may be necessary, and breakage of an embedded Paragard during non-surgical removal has been reported. It also reports 13 perforations among 5,344 clinical-trial insertions, a 0.2% figure. That is a perforation statistic, not a removal-breakage rate. Postmarketing reports cannot establish incidence because the number of devices exposed and completeness of reporting are unknown.

December 2020: federal breakage cases are centralized

On December 16, 2020, the JPML created MDL 2974 and assigned it to Judge Leigh Martin May in the Northern District of Georgia. The transfer order covered 55 actions in 31 districts and noted more than 25 potentially related federal cases. Plaintiffs shared allegations that the device could break during removal, requiring retrieval procedures and causing pain, infertility, or other injuries. Defendants disputed the allegations and liability.

Centralization made common discovery, service, document production, and motion practice more efficient. It did not certify a class or declare Paragard defective. The court's master pleadings and plaintiff fact sheets organized information, while each action retained issues such as device identity, removal circumstances, retained-fragment evidence, medical consequences, warnings, causation, and applicable state law.

2022-2024: the court builds a bellwether pool

The court entered scheduling and fact-sheet orders in 2022, then issued a February 22, 2023 order establishing major features of the bellwether process. The eligible pool focused on plaintiffs who alleged that a Paragard device broke upon removal and who had substantially complete fact sheets and authorizations. Later amendments refined selection, discovery, and trial planning. Bellwether eligibility was a procedural screen, not a determination that a claim would prevail.

During 2024, the court revised MDL leadership and updated fact-sheet and service procedures. These administrative steps matter because a mass docket depends on usable records. A complaint can be filed before the court has tested whether implant and removal records support the pleaded event. Bellwether discovery narrows that gap by requiring both sides to develop the actual medical chronology and product evidence.

2025-2026: state-law rulings and an amended trial schedule

On February 11, 2025, the court issued a lengthy ruling on statutes of limitation and repose in specified cases. Different states use different accrual, discovery, tolling, and repose rules, so similar medical timelines can produce different legal outcomes. The order is strong evidence against websites advertising one national Paragard filing deadline. A person's insertion, removal, awareness of breakage, later procedure, residence, and forum can all matter.

The court's official orders page lists an eighth amended scheduling order dated September 12, 2025. That order set expert, Rule 702, dispositive-motion, and trial-preparation dates for selected cases extending into 2026. A schedule is a plan, not an outcome. The public summary reviewed through July 10, 2026 did not establish a universal settlement or confirm that every listed trial occurred as originally scheduled; later docket entries remain controlling.

What evidence gives this timeline personal meaning

The most important sequence is clinical: insertion date and product record; duration of use; reason for removal; resistance or embedment noted during removal; inspection of the retrieved device; imaging used to locate a fragment; hysteroscopy, laparoscopy, or other retrieval; and later symptoms. Operative notes can distinguish an actual retained arm from missing strings, malposition, insertion perforation, or another IUD complication.

Research on copper IUDs can describe perforation, retention, and fracture management, but it does not prove that a design defect caused one event. The FDA label likewise confirms reported risks without deciding a lawsuit. As of July 10, 2026, no official source reviewed provides an open courtwide claims program, fixed award schedule, or guaranteed qualification. Medical care should be based on clinical advice, while legal timing requires a jurisdiction-specific review.

Reader questions

Frequently asked questions